Indian pharmaceutical company Dr. Reddy’s Laboratories has begun the approval process for the Russian Sputnik V coronavirus vaccine for emergency use in India, the newspaper reports. Mint, citing a statement from the pharmaceutical company.
It is noted that she will present to the regulator the results of the second phase of vaccine trials, as well as the interim results of the third phase, which should be completed in the country by February 21.
In Dr. Reddy’s Laboratories said the initiation of the vaccine approval process will be a critical step in ensuring rapid access to the drug in India.
It was previously reported that San Marino became the thirtieth state to approve the Russian drug Sputnik V.
Recall that in August 2020, the Ministry of Health of the Russian Federation registered the world’s first COVID-19 vaccine Sputnik V. The third phase of clinical trials conducted in Russia, showed that the effectiveness of the drug is 91.6%.